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ABSTRACT
Objectives: An increase in IGF-I and TNF-α may be a cardioprotective effect. To examine the relationships between IGF-I and 
TNF-α and test the anthropometric and biochemical parameters before and after a low-glycemic index reduction diet 
using a correlation matrix. 
Material and methods: Twenty-two women diagnosed with PCOS according to Rotterdam’s criteria were eligible for this 
study, which analysed the results before and after a three months dietary intervention. Body composition measurements 
were determined by bioimpedance and performed twice, along with the labelling of lipid, carbohydrate and hormonal 
profiles. IGF-I and TNF-α were also determined in the serum. 
Results: Before dietary intervention, a significant correlation was observed. A correlation was also noted between the 
increase in TNF-α and DHEA-SO4, FSH, glucose level and total cholesterol. The increase in IGF-I was not related to anth-
ropometric measurements: however, its concentration was observed to be related to the level of SHBG and HDL. After 
dietary intervention, the correlation between TNF-α and muscle mass percentage was confirmed, as was the correlation 
between WHR and fasting blood glucose levels. A significant negative correlation was observed between extracellular 
water, provided in litres, and SHBG level. 
Conclusions: One important role of IGF-I in PCOS pathogenesis is the stimulation of increased synthesis of SHBG and HDL. 
The increased level of IGF-I after the reduction diet had a cardioprotective effect. TNF-α inhibits FSH synthesis, preventing 
the growth of numerous follicles. Its synthesis is also related to DHEA-SO4. After three-month reduction diet does not 
significantly reduce TNF-α.
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INTRODUCTION
In serum, the amount of free IGF-I (insulin-like growth 
factor 1) does not exceed 5%, and the main binding pro-
tein is IGFBP-3 [1]. Binding proteins extend the half-life 
and prevent hypoglycaemia induced by IGF-I. Free form 
IGF-I binding to a specific receptor often homologous to 
the insulin receptor, induces cells growth and extends their 
life, preventing apoptosis. IGF-I is characterized by para- and 
autocrynic pleiotropic activity in many tissues. Because its 
structure is to insulin, IGF-I has hypoglycaemic activity al-
though it is weaker than in the case of insulin. The synthesis 
of IGF-I depends on age, sex, circadian cycles, genetic factors 
and chronic diseases; it correlates with menopause and 
bone age [2]. Studies indicate a reverse correlation between 
the concentration of IGF-I and body mass index (BMI) [3]. 
In other studies, it was observed that individuals with vis-
ceral obesity may have lower levels of IGF-I in comparison 
with those with the gynoid type of obesity [4]. There are 
numerous data supporting the involvement of IGF-I in the 
formation and development of malignant tumours. In some 
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tumours, the level of IGF-I is regarded as a potential marker 
of cancerous processes [5]. Overexpression of the gene 
encoding for IGF-I was also observed in polycystic ovary 
syndrome (PCOS), where the increase in IGF-I concentration 
mainly because of liver synthesis intensifies the aromatiza-
tion of androstenedione and testosterone from theca cells 
to oestradiol [3]. A positive correlation was also confirmed 
between circulating IGF-I and the risk of breast cancer [6]. 
The majority of studies seem to confirm significant involve-
ment of IGF-I in the pathogenesis of cardiovascular diseases 
that are often observed in women with PCOS [7]. The role 
of IGF-I in the pathogenesis of these diseases is unclear 
because IGF-I binds to the receptor and through tyrosine 
kinase is involved in the cascade of reactions leading to the 
synthesis of NO or MAPK, which has a cardioprotective role. 
Studies on the understanding of the molecular mechanisms 
of IGF-I activity are still ongoing and can play a significant 
role in recognizing the aetiology of various diseases. 
Research has shown that the increase in IGF-I in patients 
with PCOS is correlated with insulin resistance; furthermore, 
these patients are at a higher risk of developing breast, cervi-
cal and ovarian cancer [8]. The lack of a hormonal balance 
which causes disruptions between the hypothalamus pituitary 
gland and ovaries is also one of the causes of PCOS [9]. Silfen 
et al. noted that IGF-I enhances steroid cycles [10]. Moreover, 
IGF-I secretion depends on tumour necrosis factor (TNF-α). 
TNF-α is a cachectin that is mainly produced by mac-
rophages. Its biological activity depends on its concentra-
tion. A low concentration induces autocrynic and paracrynic 
regulation of the immune response and at high concentra-
tions, TNF- α has endocrynic activity [11]. The concentration 
of TNF-α in the serum is modulated by various cytokines, 
hormones and soluble forms of receptors causing its neu-
tralization [12]. Its biological role is very complex because 
it influences the release of prostaglandins, leukotrienes, 
factors activating platelets, nitrogen oxide (NO) and reac-
tive forms of oxygen. At the same time, it is a cytokine 
that regulates the expression of numerous genes and has 
cytotoxic activity against tumour cells via ceramide cas-
cade and cell apoptosis. TNF-α influences the processes 
of ovulation, fertilization and implantation of an embryo, 
making it an important factor in PCOS pathogenesis [13]. 
A higher level of androgens increases the release of TNF-α 
from mononuclear cells (MNC) [14]. In our study, we tried to 
determine the effect of TNF-α and IGF-I on anthropometric 
and biochemical parameters of patients with PCOS and the 
changes occurring after using a reduction diet and increased 
physical activity in this group of women. An increase in 
physical activity and the use of a reduction diet aims to 
reduce white adipose tissue and lower the concentration 
of TNF-α and IL-1 in laboratory animals [15]. A positive ef-
fect of a low glikemic index GI diet in PCOS treatment has 
already been suggested by other researchers [16], but the 
scope of our study is broader and gives an opportunity to 
assess metabolic changes in a wider context. Marsh et al. 
have demonstrated a more beneficial effect of reduction 
diet with low GI with a reduction diet with higher glikemic 
index for regulating the monthly cycle of PCOS women [16].
MATERIAL AND METHODS
Test group
Screening tests to diagnose PCOS were performed on 
39 women with an average age of 26.76 ± 5.08 years old. To 
perform the study, the consent of the Bioethical Commission 
of the Pomeranian Medical University was obtained: No. 
KB-0012/134/12, with the addendum to the permission No. 
KB-0012/36/14. All patients gave written informed consent, 
and their confidentiality and anonymity were protected. 
A PCOS diagnosis was carried out based on the Rotterdam 
criteria, using USG (Ultrasound Voluson 730, GE, Switzer-
land). The test group was comprised of Caucasian women 
with an average body weight of 79.13 ± 14.57 kg and aver-
age height of 1.67 ± 0.06 cm.
Measurements of body weight, height and body com-
position were performed using a BIA 101 device with the 
electric bioimpedance method (Akern, Italy). After 3-month 
period of the diet, three women were excluded from the 
study because of pregnancy, 10 women did not attend the 
control examination and 4 women were excluded because 
they did not use the diet, only the recommendations, and 
did not achieve the minimum body mass reduction of 2 kg. 
Finally, the test group included 22 women with PCOS with 
a average age of 26.62 ± 4.18 years old. The parameters of 
the examined group of women with PCOS before and after 
the diet intervention are presented in Table 1.
Biochemical measurements
The samples were centrifuged at 3500 rpm for 10 min at 
4°C within 15 min of collection. The serum was transformed 
into 1.5 mL Eppendorf tubes and frozen at –80°C until the 
analyses of TNF-α and IGF-I were performed; the two pa-
rameters were measured with commercially available kits 
from Cayman Chemical Company (EIA Kit Item No. 589201, 
Ann Arbor, USA) and Quantikine ELISA R&D Systems (Min-
neapolis, USA & Canada Manufactured), respectively.
Blood for hormone analysis was collected from all of the 
patients in day 3–5 of the menstrual cycle. Follicle-stimulat-
ing hormone mIU/mL (FSH), luteinizing hormone mIU/mL 
(LH), oestradiol pg/mL (E2), testosterone ng/mL (T), prolactin 
ng/mL (PRL) and sex hormone-binding globulin nmol/L 
(SHBG) were analysed with ECLIA (electro-chemilumines-
cence immunoassay), androstenedione was analysed us-
ing ELISA (Kobas Rosch E411), and DHEA-SO4 µg/dL was 
analysed using an immunoenzymatic technique. 
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Table 1. Characteristics of the test group before and after the dietary intervention 
Parameter
Before After
p
Mean Range SD Mean Range SD
Na/K 0.91 0.8–1.3 0.13 0.92 0.8–1.3 0.12 NS
TBW [%] 45.47 36.8–52.7 5.25 47.14 40.9–53.6 4.42 NS
TBW IN [%] 53.52 47.4–56.6 2.45 53.53 38.9–58.3 3.54 NS
TBW EX [%] 43.26 43.1–61.1 9.27 46.40 42.6–52.7 3.43 NS
TBW [L] 35.57 29.7–50.9 3.99 34.21 29.7–39.9 3.41 NS
TBW IN [L] 18.52 15.2–30.9 2.75 18.29 12.2–23.8 2.63 NS
TBW EX [L] 16.48 14.2–25.5 1.54 15.86 14.2–22.1 1.53 NS
Phase angle PA 5.86 4.7–6.6 0.50 5.87 4.5–7.7 0.74 NS
Body mass [kg] 79.13 63.8–112.5 14.58 73.01 61–97.5 10.18 p < 0.05
fat mass [%] 37.92 27.3–47.6 7.16 35.57 26.7–41.3 6.06 NS
fat mass [kg] 30.70 18.1–48.8 9.72 26.60 17.2–43 8.08 p < 0.05
BCM [kg] 24.21 10.7–34.3 5.95 24.79 16.1–32.7 3.70 NS
BCM [%] 52.93 40.4–56.2 2.65 52.92 37.5–61.2 3.77 NS
Muscle mass [kg] 34.16 25.7–47.6 6.91 35.39 23.2–54.5 8.66 NS
Muscle mass [%] 41.58 34.6–60.7 7.45 48.35 28.2–65.9 9.18 p<0.01
Waist circumference [cm] 97.90 78.5–117 12.13 90.41 73–107.5 12.71 p<0.05
Hip circumference [cm] 107.89 96–124 8.45 105.17 88.5–117 9.57 NS
Arm circumference [cm] 30.95 25–38 3.79 29.36 22.5–39 4.99 NS
Skinfold above ilium [mm] 29.32 20.0–43.0 7.32 23.15 14.0–39.0 6.14 p < 0.01
Skinfold below shoulder blade [mm] 27.26 12.5–36.0 8.78 23.75 15.0–31.5 6.93 p < 0.05
Arm skinfold [mm] 25.62 13.5–37.0 8.76 21.14 13.5–33.0 6.85 p < 0.05
BMI [kg/m2] 28.79 19.7–38.34 5.56 26.55 19.5–36.25 7.33 p < 0.05
WHR 0.901 0.8–1.02 0.07 0.86 0.72–0.95 0.08 p < 0.05
DHEA-SO4 [µg/dL] 227.78 112–357 66.78 228.41 96–326 74.44 NS
Androstendion ng/mL] 4.56 1.5–8.2 1.60 3.90 2.6–7.45 1.38 p < 0.05
LH [mIU/mL] 7.07 5.74–17.02 1.84 4.97 2.8–8.23 1.54 p < 0.05
FSH [mIU/mL] 5.32 2.7–7.87 1.45 5.26 2.58–7.74 1.51 NS
Oestradiol [pg/mL] 40.26 16.7–119.73 14.09 44.69 20.05–69.4 27.08 NS
SHBG [nmol/L] 39.39 19.05–66.2 15.94 44.34 18.1–79.9 21.29 NS
Testosterone [ng/mL] 0.57 0.28–1.3 0.28 0.46 0.33–0.79 0.11 p < 0.05
Prolactin [ng/mL] 16.82 8.3–23.3 6.11 13.56 8.7–19.6 3.22 p < 0.05
Insulin test 0 [mU/L] 18.56 4.6–64.4 16.69 11.38 4.5–17.7 4.22 p < 0.05
Insulin after 2h [mU/L] 68.27 7.2–384 47.24 59.40 17.2–114.2 28.01 p < 0.05
Glucose [mg/dL] 93.07 84.08–106.3 5.49 89.30 76.65–97.7 6.10 p < 0.05
Glucose after 2h [mg/dL] 112.6 80.26–162.7 23.40 107.85 59.6–151.65 26.37 NS
Cholesterol [mg/dL] 224.52 136.2–197.6 25.3 172.45 142.5–194.7 22.15 p < 0.05
LDL [mg/dL] 129.37 78.8–150.2 29.58 98.32 78.3–123.5 16.45 p < 0.01
TRIGL [mg/dL] 132.73 59.5–156.3 39.78 71.2 53.1–139.7 29.64 p < 0.05
HDL [mg/dL] 59.13 34.03–103.3 20.76 61.54 43.7–106.6 20.02 NS
IGF-I [ng/mL] 89.42 048–1.85 0.35 96.988 0.35–1.68 0.33 p < 0.01
TNF-alfa [pg/mL] 59.69 35.79–104.4 18.22 57.626 43.48–98.83 12.32 NS
298
Ginekologia Polska 2018, vol. 89, no. 6
www. journals.viamedica.pl/ginekologia_polska
Dietary intervention
Each of the participants received a 7-day diet that was 
individually adjusted to energy requirements and recom-
mendations regarding lifestyle changes. The quantitative 
compositions of diets were calculated using Diet 4.0 soft-
ware, which was recommended by National Food and Nu-
trition Institute (NFNI). Contens energy, nutrients, minerals, 
vitamins dietary fibre and cholesterol, were determined. 
Calories in the diets were reduced by 600 kcal with respect to 
energy requirements. Carbohydrate products had lowered 
glyceamic index (coarse grits, wholemeal products, taking 
into consideration vegetable fat). The sources of protein 
in the diet (on average 1 portion of meat and 2 portions 
of dairy products a day) were as follows: eggs, lean meat 
without skin (chicken, turkey), saltwater fish (cod, salmon, 
tuna), semi-skimmed pasteurized milk and dairy products 
(quark, natural yoghurt and buttermilk with 2% fat). The diet 
included dried pulses (soy, red lentils, beans, peas).
The sources of fat (on average, 2 portions per day) were 
cold oils in raw form (rapeseed oil, olive oil), oily fruits, such 
as avocado; nuts (almonds, pumpkin seeds, sunflower seeds, 
sesame seeds and poppy seeds), and oily fish. The diet also 
included low GI vegetables and fruits.
For food preparation, it was recommended to use the 
following heat treatment techniques: braising, roasting, 
cooking in water and steaming. Moreover, each patient was 
recommended to drink ca. 2 litres of fluid during the day. The 
recommended were iodized water and herbal infusions. The 
average weekly ratio of energy was up to 20% from protein, 
up to 30% from fat and ca. 50% from carbohydrates. The 
consumption of cod liver oil was recommended from Oc-
tober to April.
Statistical analysis
The results are expressed as the mean ± standard devia-
tion. As the distribution in most cases deviated from normal 
(Shapiro-Wilk test), anon-parametric Mann-Whitney test 
was used for comparisons between groups, and p < 0.05 or 
p < 0.01 was considered statistically significant. Statistical 
analysis was performed with Statistica 12.0 (Statsoft, Tulsa, 
Oklahoma, USA) using acorrelation matrix with relation 
to anthropometric and biochemical parameters. The pro-
gram uses basic statistics, correlation matrix, two variable 
lists. The correlation coefficients determined are significant 
at p < 0.05.
RESULTS
The correlation matrix with respect to anthropometric 
parameters showed a significant correlation between TNF-α 
and the increase in total body water in the organism (TBW%, 
TBW-IN%, TBW-EX%, TBW-litre, TBW IN litre) and body cell 
mass (BCM %, m mass kg, m mass %) also manifested by 
arm and hip circumferences and WHR (Tab. 2). A correlation 
was also noted between the increase in TNF-α and the fol-
lowing biochemical parameters: DHEA-SO4, FSH, glucose 
level (under fasting conditions and after 2 hours) and total 
Table 2. Correlation matrix representing the correlation of IGF-I and 
TNF-α with anthropometric and biochemical parameters before 
dietary intervention
Parameter IGF-I ng/mL TNF-α pg/mL
Na/K –0.432 –0.079
TBW [%] 0.637 0.837
TBW IN [%] 0.369 0.767
TBW EX [%] 0.257 0.688
TBW [L] 0.220 0.728
TBW IN [L] 0.242 0.742
TBW EX [L] 0.147 0.653
Phase angle PA 0.138 –0.010
Fat mass [%] –0.140 0.414
Fat mass [kg] –0.308 0.215
BCM [kg] 0.316 0.635
BCM %] 0.375 0.771
M mass [kg] 0.425 0.904
M mass [%] 0.634 0.737
Waist circumference [cm] 0.022 0.627
Hip circumference [cm] 0.204 0.686
Arm circumference [cm] 0.206 0.706
Skinfold shoulder blade [mm] –0.301 0.442
Skinfold hip [mm] –0.183 0.641
Skinfold arm [mm] –0.068 0.520
WHR 0.146 0.722
BMI [kg/m2] 0.334 0.614
DHEA-SO4 [µg/dL] 0.257 0.768
Androstenedione [ng/mL] 0.018 0.111
LH [mIU/mL] –0.293 0.329
FSH [mIU/mL] 0.214 0.683
Oestradiol [pg/mL] –0.597 0.159
SHBG [nmol/L 0.700 0.197
Testosterone [ng/mL] 0.368 0.570
Prolactin [ng/mL] 0.432 0.296
Insulin test 0 [mU/L] 0.239 0.414
Insulin after 2h [mU/L] 0.244 0.618
Glucose [mg/dL 0.375 0.742
Glucose after 2h [mg/dL 0.180 0.848
Cholesterol [mg/dL] 0.580 0.675
LDL [mg/dL] 0.318 0.649
TRIGL [mg/dL] –0.386 0.497
HDL [mg/dL] 0.761 0.158
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cholesterol. An increase in IGF-I related to anthropometric 
measurements was not observed, but it was noted that 
its concentration correlated with the level of testosterone 
binding protein (SHBG) and HDL (Tab. 2).
After dietary intervention, the correlation between 
TNF-α and anthropometric and biochemical parameters 
differed from that before the use of the reduction diet. The 
correlation between TNF-α and % muscle mass, WHR and 
fasting blood glucose level was confirmed. A significant 
negative correlation was also observed with relation to ex-
tracellular water (TBW EX), given in litres, and the SHBG level 
(Tab. 3). Correlations between IGF-I and anthropometric and 
biochemical parameters after the dietary intervention were 
as follows: IGF-I was significantly correlated with the level 
of testosterone and was negatively correlated with muscle 
mass in kg (m mass kg), upper-arm skinfold measured under 
the shoulder blade, skinfold measured above the crest of 
the ilium, and glucose level measured 2 h after a glucose 
load (Tab. 3). 
DISCUSSION
Correlation of IGF-I before and after dietary 
intervention 
An increase in IGF-I with anti-inflammatory activity 
through the capture of glucose and regulation of its me-
tabolism may result from the excessive consumption of 
glucose and the development of obesity in women with 
PCOS. IGF-I also affects lipid metabolism in the organism 
by reducin the levels of triglycerides and free fatty acids in 
the serum. To summarize, the metabolic effect of IGF-I mani-
fests by increasing the insulin sensitivity of the organism. 
IGF-I enhances the ability of macrophages to absorb LDL and 
the ability to further synthesize cytokines and chemotactic 
factors. Thus, its activity is pleiotropic. 
Moreover, IGF-I was shown to increase the sensitivity 
of the ovaries to gonadotropin stimulation and indirectly 
affects follicle growth and oocytes maturation. It inhib-
its the apoptosis occurring in the follicles and thus most 
likely affects folliculogenesis and the proper development 
of the ovary. IGF-I is regarded as one of the basic factors 
responsible for complications in the form of nephropathy in 
patients with diabetes, in which the occurring proliferation 
of mesangial and stromal cells leads to glomerulopathy [17]. 
IGF-I also promotes angiogenesis in diabetic nephropathy; 
therefore, the drugs inhibiting the GH/IGF-I axis could be 
used in PCOS treatment [18].
In the case of IGF-1 before the introduction of the diet, 
it was correlated with only a few variables: higher concen-
trations of SHBG and HDL. The increase in HDL suggests 
a cardioprotective effect of IGF-I linked to higher synthesis 
with a lower concentration of the active form of testoster-
one. A similar correlation between HDL and IGF-I in patients 
suffering from type II diabetes and children with metabolic 
syndrome was observed by other researchers [19]. However, 
Liang et al. speculated that IGF-1 might exert some direct or 
indirect effects on HDL-C metabolism. Perhaps IGF-1 inhibits 
the expression of class BI hepatic scavenger receptor (SRB1) 
Table 3. Correlation matrix representing the correlation of IGF-I and 
TNF-α with anthropometric and biochemical parameters after 
dietary intervention
Parameter IGF ng/mL TNF pg/mL
Na/K 0.244 –0.209
TBW [%] 0.160 –0.102
TBW IN [%] –0.299 0.325
TBW EX [%] 0.273 –0.312
TBW [L] –0.191 –0.310
TBW IN [L] –0.355 –0.026
TBW EX [L] 0.101 –0.446
Phase angle PA –0.313 0.304
Fat mass [%] –0.159 0.102
Fat mass [kg] –0.230 –0.034
BCM [kg] –0.367 –0.009
BCM [%] –0.296 0.322
M mass [kg] –0.462 0.270
M mass [%] –0.404 0.497
Waist circumference [cm] –0.189 0.186
Hip circumference [cm] –0.138 –0.176
Arm circumference [cm] –0.377 0.173
Skinfold shoulder blade [mm] –0.434 0.068
Skinfold hip [mm] –0.423 0.045
Skinfold arm [mm] 0.090 0.013
WHR –0.190 0.503
BMI [kg/m2] 0.354 0.352
DHEA-SO4 [µg/dL] 0.177 0.040
Androstenedione [ng/mL] 0.335 0.221
LH [mIU/mL] 0.358 0.304
FSH [mIU/mL] –0.183 0.048
Oestradiol [pg/mL] 0.192 0.186
SHBG [nmol/L] 0.170 –0.438
Testosterone [ng/mL] 0.458 –0.097
Prolactin [ng/mL] 0.226 0.066
Insulin test 0 [mU/L] 0.282 0.078
Insulin after 2h [mU/L] –0.256 0.029
Glucose [mg/dL] 0.051 0.693
Glucose after 2h [mg/dL] –0.438 0.340
Cholesterol [mg/dL] 0.119 –0.094
LDL [mg/dL] –0.315 0.099
TRIGL [mg/dL] 0.267 0.384
HDL [mg/dL] 0.376 –0.416
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on the surface of liver Hep2 B cells, leading to a reduction in 
HDL reverse transport and an increased circulating HDL-C 
concentration [20]. Another factor may influence HDL-C, 
at least partially, by improving the insulin sensitivity [21]. 
However, another cause of the correlation may be the asso-
ciation between IGF-1 and HDL-C driven by growth hormone 
(GH) [22]. Because the active form of testosterone and GH 
directly affect IGF-I synthesis in liver cells, it seems that the 
coexistence of these two factors modulates the synthesis 
of HDL via IGF-I. 
After using the low GI reduction diet, a positive correlation 
was observed between IGF-I and testosterone, and a nega-
tive correlation was observed — between IGF-I and muscle 
mass (in % and kg), skinfold thickness below the shoulder 
blade, skinfold above the crest of the ilium, and the level of 
glucose after 2 h (OGTT). The observed correlation suggests 
that the synthesis of IGF-I could be affected by testosterone 
and improvement in glucose tolerance after a meal (OGTT). 
Synthesis of IGF-I was related to the reduction of visceral 
adipose tissue and the reduction of torso fatness because 
IGF-I enhances protein synthesis. It seems that in women with 
PCOS the basic function of OGF-I is to increase the synthesis of 
proteins [23], especially SHBG transporting steroid hormones 
(mainly testosterone) and HDL cholesterol (a fraction with the 
highest content of apolipoproteins) [24]. This is confirmed by 
the results of IGF-I correlation after the reduction diet, sug-
gesting increased synthesis of IGF-I along with a reduction in 
muscle mass (in % and kg). It also seems that the increased 
synthesis of IGF-I could be caused by compensation for lost 
muscle mass. Simultaneously, its higher level stimulated 
the reduction of adipose tissue in the torso, as measured 
by skinfold thickness and to a lesser extent in peripheral 
tissues. Moreover, the increased concentration of IGF-I, as 
a molecule similar to insulin in structure and biological activ-
ity influenced better glucose tolerance and glycaemia after 
a meal [25]. In diabetes, we observe a decrease in quick release 
insulin after a meal, when the level of glucose increases and 
a delayed release of insulin. Insulin increases muscle mass if 
accompanied by increased microcirculation and a surplus of 
amino acids [26]. It should be remembered that in the course 
of developing an inflammatory process that occurs in women 
with PCOS the effect of IGF-I is weakened because various 
cytokines inhibit its expression [27]. Therefore, an increased 
IGF-I level after using a reduction diet should be treated as 
a cardioprotective effect (Fig. 1).
Correlation of TNF-α before  
and after dietary intervention
Observed correlations for TNF-α in women with PCOS 
before dietary intervention clearly relate to anthropometric 
parameters linked to higher testosterone activity [28]. The 
effect of androgens on the increase of TNF-α was also ob-
served by Gonzalez et al [14]. Anthropometric parameters 
that are connected to higher testosterone level and amount 
of adipose tissue, which are often present in women with 
PCOS, can involve the following parameters relating to total 
body water in the organism and muscle mass: TBW %, TBW 
IN%, TBW EX%, TBW litre, TBW IN litre, BCM %, m mass kg, 
m mass % and the circumference of hip (gluteus) and arm 
(triceps). 
Figure 1. IGF-I and TNF-α mechanisms of action in PCOS 
IGF — insulin-like growth factor 1; TNF — tumor necrosis factor α
IGF and TNF-α mechanism
of action during body mass reduction
Increased synthesis of testosterone
receptor in muscle cells
Anti-inammatory activity regulation
of glucose metabolism
Muscle mass
Insulin resistance SHBG
IGF-1
TNF-α
Inammation
Level of glucose
Level of glucose
Body mass
Visceral adipose tissue
(WHR)
Cholesterol
Androgenes Testosteron
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In our earlier study, we observed the correlation be-
tween DHEA-SO4 and TNF-α, suggesting that the mecha-
nism of TNF-α synthesis is linked to enhancement of the 
Λ4 pathway [29]. Therefore, the same correlation occurring 
before the diet confirms our earlier observations. It should 
be noted that DHEA-SO4 is produced from cholesterol by 
the adrenal cortex via sulfation justifying the positive cor-
relation between TNF-α and the level of total cholesterol 
before dietary intervention.
Regarding the correlations between TNF-α and hor-
mones, it was noted that the higher level of TNF-α is re-
lated to an increased concentration of follicle-stimulating 
hormone (FSH). Follicle development processes are largely 
dependent on the stimulating effect of FSH through its re-
ceptor that is only located in granulosa cells. After reaching 
the size of ca. 7 mm in diameter, one of the follicles becomes 
a dominating one and develops further, whereas others 
die through apoptosis initiated by TNF-α in granulosa cells 
[30]. Thus, TNF-α has a protective function in ovary ageing 
because it drastically reduces FSH at the gene transcription 
level [31] and inhibits the synthesis of oestrogens [32].
We also observed the correlation between TNF-α and 
WHR. A similar relationship in obese children was reported 
by Goral et al. However, they did not determine the direct 
relationship between BMI and the amount of adipose tissue 
in obese girls, similarly to our own studies [33]. The logical as-
sumption would be that TNF-α is synthesized by macrophag-
es in adipose tissue, visceral adipose tissue in particular [34].
After the low GI reduction diet, we also observed a posi-
tive correlation between TNF-α and the level of fasting glu-
cose, suggesting improvement in glucose tolerance after 
three months of the diet (because of the lack of correlation 
with glucose concentration 2 h after a meal). Positive cor-
relations between TNF-α and fasting glucose, both before 
and after the reduction diet, confirm the involvement of 
this modulator in the development of type II diabetes be-
cause of the dysfunction of the insulin receptor and reduced 
expression of GLUT 4 [35]. However, the results of studies 
performed among the obese do not confirm a significant 
role of TNF-α in the development of insulin resistance [12].
After the reduction diet negative correlations were ob-
served between TNF-α and the level of extracellular water 
and SHBG. An increased level of SHBG decreased the level 
of active testosterone and is linked to metabolic effects of 
TNF-α. A lower concentration of testosterone after the diet 
can thus be attributed to a reduced amount of intracel-
Figure 2. IGF-I and TNF-α mechanisms of action during body mass reduction 
IGF-1 — insulin-like growth factor 1; TNF — tumor necrosis factor α; HDL — high-density lipoprotein; SHBG — sex hormone binding globulin; 
FSH — follicle-stimulating hormone; GLUT 4 — glucose transporter type 4; DHSO4 — dehydroepiandrosterone sulfate; NFkB — nuclear factor-κB 
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lular water being the result of potassium intake with the 
diet (on average 4421 ± 650 mg/day) and a reduced level 
of sodium in the diet (on average 1692 ± 497 mg/day). All 
of the relationships and metabolic functions of IGF-I and 
TNF-α in PCOS pathogenesis that are discussed above are 
presented in Figure 1 and Figure 2. 
CONCLUSIONS
One of the major roles of IGF-I in PCOS pathogenesis is 
stimulation of the synthesis of SHBG and HDL. The increase of 
IGF-I level after the reduction diet has a cardioprotective effect. 
Thus, the inclusion of measuring IGF-1 and HDL levels might be 
warranted in the assessment protocols for obese women with 
PCOS to verify possible complications of early cardiovascular 
alterations. Enhanced synthesis of TNF-α by visceral adipose 
tissue in women with PCOS contributes to the development 
of glucose intolerance and type II diabetes. TNF-α inhibits the 
synthesis of FSH, disabling the growth of numerous follicles, 
and its synthesis is correlated with DHEA-SO4. Reduction diet 
does not significantly reduce synthesis TNF-α.
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